The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1

Journal of Gastroenterology

Volumn 50, Issue 3, 2015, Pages 313-322

  Oze, Tsugiko ^a   Hiramatsu, Naoki ^a   Yakushijin, Takayuki ^a   Yamada, Ryoko ^a   Harada, Naoki ^a   Morishita, Naoki ^a   Yamada, Akira ^b   Oshita, Masahide ^c   Kaneko, Akira ^c   Suzuki, Kunio ^d   Inui, Yoshiaki ^e   Tamura, Shinji ^f   Yoshihara, Harumasa ^g   Imai, Yasuharu ^h   Miyagi, Takuya ^a   Yoshida, Yuichi ^a   Tatsumi, Tomohide ^a   Kasahara, Akinori ⁱ   Hayashi, Norio ^j   Takehara, Tetsuo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SUMITOMO HOSPITAL   (Japan)

^c OSAKA POLICE HOSPITAL   (Japan)

^d SAISEIKAI SENRI HOSPITAL   (Japan)

^e Hyogo Prefectural Nishinomiya Hospital   (Japan)

^f Minoh City Hospital   (Japan)

^g OSAKA ROSAI HOSPITAL   (Japan)

^h IKEDA MUNICIPAL HOSPITAL   (Japan)

ⁱ OSAKA UNIVERSITY HOSPITAL   (Japan)

^j KANSAI ROSAI HOSPITAL   (Japan)

more..

Author keywords

Chronic hepatitis C; Dose reduction; Pegylated interferon plus ribavirin; Telaprevir

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

AGED; ANEMIA; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ERUPTIONS; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIROLOGY;

AGED; ANEMIA; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84939881464     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-014-0965-8     Document Type: Article

References (19)

1. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.
2. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–38.
3. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–50.
4. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292–303.
5. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.
6. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014–24.
7. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28.
8. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78–84.
9. Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:134–42.
10. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)—NCT01514890. J Hepatol. 2013;59:434–41.
11. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006;131:997–1002.
12. Suzuki F, Akuta N, Suzuki Y, et al. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatol Res. 2009;39:1056–63.
13. Suzuki F, Suzuki Y, Sezaki H, et al. Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. Hepatol Res. 2013;43:691–701.
14. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–93.
15. Kawakami Y, Suzuki F, Karino Y, et al. Telaprevir is effective given every 12 hours at 750 mg with peginterferon-alfa-2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT. Antivir Ther. 2013. doi:10.3851/IMP2706.
16. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58:1918–29.
17. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014;146:430–41.
18. Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2014;49:138–47.
19. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;52:421–9.